0001104659-23-035170.txt : 20230321 0001104659-23-035170.hdr.sgml : 20230321 20230321172818 ACCESSION NUMBER: 0001104659-23-035170 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230317 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230321 DATE AS OF CHANGE: 20230321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Praxis Precision Medicines, Inc. CENTRAL INDEX KEY: 0001689548 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39620 FILM NUMBER: 23750605 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-300-8460 MAIL ADDRESS: STREET 1: 99 HIGH STREET, 30TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 tm239181d2_8k.htm FORM 8-K
0001689548 false 0001689548 2023-03-17 2023-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 17, 2023

 

 

 

PRAXIS PRECISION MEDICINES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-39620 47-5195942

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, Massachusetts 02110

(Address of principal executive offices, including zip code)

 

(617) 300-8460

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trade

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   PRAX   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 17, 2023, Nicole Sweeny, Chief Commercial Officer of Praxis Precision Medicines, Inc. (the “Company”), and the Company determined that, considering the current priorities of the Company, Ms. Sweeny would depart from the Company, effective March 31, 2023. Ms. Sweeny’s departure is not the result of any dispute or disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

 

On March 21, 2023 (the “Separation Date”), the Company and Ms. Sweeny entered into a Separation Letter Agreement (the “Separation Agreement”) pursuant to which, provided that Ms. Sweeny does not revoke the Separation Agreement within seven days of signing it and complies with the terms of the Separation Agreement, including her grant of a general release of claims in favor of the Company and its affiliates, the Company will (i) continue to pay Ms. Sweeny’s base salary for a period of nine months from the Separation Date (the “Severance Period”) and (ii) should Ms. Sweeny elect to continue receiving group medical and dental coverage through COBRA, continue to pay the portion of the premium for Ms. Sweeny’s coverage that it would pay for active and similarly situated employees during the Severance Period, unless Ms. Sweeny is no longer eligible for COBRA coverage or becomes eligible for coverage by a subsequent employer. The Separation Agreement also includes other customary provisions.

 

The foregoing description is qualified in its entirety by the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 8.01. Other Events.

 

The Company has conducted a periodic evaluation of its priorities, focused on delivering key milestones, including completion of the end of phase 2 meeting with the FDA for ulixacaltimide that would then enable initiation of a Phase 3 study for the treatment of essential tremor, and the read-out of its current studies for PRAX-562 and PRAX-222. As a result of the evaluation, the Company has realigned its projected expenses and personnel needed to deliver on those milestones, which the Company expects will extend its current cash runway into the second quarter of 2024.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the clinical development of ulixacaltamide, the timing of current studies for PRAX-562 and PRAX-222, and the Company’s cash runway. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, uncertainties and assumptions, including, without limitation, uncertainties inherent in clinical trials, the expected timing of submission for regulatory approval or review by governmental authorities and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and its other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
  Description
10.1   Separation Letter Agreement, dated as of March 21, 2023, by and between Praxis Precision Medicines, Inc. and Nicole Sweeny
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PRAXIS PRECISION MEDICINES, INC.
   
Date: March 21, 2023 By: /s/ Marcio Souza
    Marcio Souza
    Chief Executive Officer

 

 

 

EX-10.1 2 tm239181d2_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

 

 

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, MA 02110

www.praxismedicines.com

 

Privileged and Confidential

 

March 21, 2023

 

Nicole Sweeny

 

Re: Separation Letter Agreement

 

Dear Nicole,

 

This letter confirms (1) the termination of your employment relationship with Praxis Precision Medicines, Inc. (“Praxis”), and (2) your separation from Praxis (the “Agreement”). This Agreement outlines the parties’ formal separation.

 

You acknowledge that you are entering into this Agreement knowingly and voluntarily. It is customary in employment separation agreements for the departing employee to release the employer from any possible claims, even if the employer believes, as is the case here, that no such claims exist. By proposing and entering into this Agreement, Praxis is not admitting in any way that it violated any legal obligation that is or was owed to you.

 

With those understandings, the parties agree as follows:

 

1.Separation from Employment

 

This confirms that your employment with Praxis is ending effective on March 31, 2023 (the “Separation Date”). Praxis shall pay you (a) all wages that are due to you up to and through the Separation Date, (b) any expense reimbursements owed to you in accordance with the Praxis’ expense reimbursement policy and (c) any amount accrued and arising from your participation in, or benefits accrued under any employee benefit plans, programs or arrangements of Praxis, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements. If you apply to the Massachusetts Department of Unemployment Assistance for unemployment compensation benefits under state law, Praxis shall not dispute your eligibility for such benefits. This shall not affect Praxis’ obligation to respond truthfully to governmental agency requests for information related to unemployment compensation eligibility.

 

2.Severance Benefits

 

(a)           Severance Pay. Based on your adherence to the covenants, representations, warranties and obligations set forth in this Agreement, Praxis agrees to pay you separation payments of $337,500.00 (“Severance Pay”), consisting of 9 months of salary. The Severance Pay will be paid to you in substantially equal installments on Praxis’ normal payroll schedule over the 9 month period following the Separation Date, beginning on the first payroll after the Effective Date of this Agreement, which initial payment shall include any amounts that otherwise would have been paid to prior to such first payroll date. The Severance Pay shall be subject to applicable deductions and withholdings. You will not receive any additional compensation from Praxis other than that which is specified herein.

 

 

 

 

(b)           Health Benefits. If you elect COBRA continuation coverage, Praxis shall pay the same portion of premiums that it pays for active employees, for the same level of group coverage as in effect for you on the Separation Date, until the earliest of the following: (i) 9 months following the Separation Date; (ii) your eligibility for group coverage through other employment; or (iii) the end of your eligibility under COBRA for continuation coverage for medical care. You will be responsible for paying the remaining portion of the premiums for such coverage as if you remained employed. You agree to notify Praxis promptly if you become eligible for group coverage through another employer. You also agree to respond promptly and fully to Praxis regarding any reasonable requests for information concerning your eligibility for such coverage. You may continue coverage after the end of the Severance Pay period at your own expense for the remainder of the COBRA continuation period, subject to continued eligibility. Notwithstanding the foregoing, if Praxis determines at any time that its payments pursuant to this subsection may be taxable income to you, it may convert such payments to payroll payments directly to you on Praxis' regular payroll dates, which shall be subject to tax-related deductions and withholdings. If Praxis determines that it cannot provide for COBRA coverage, it shall make such Special Cash Payments as described in Section 5.2(b) of your Employment Agreement.

 

3.Continuing Obligations

 

You acknowledge that your obligations under your Employee Confidentiality, Assignment, and Nonsolicitation Agreement, executed by you on July 20, 2020 (“Confidentiality Agreement”), shall continue in full force and effect, including without limitation, your obligations to maintain the confidentiality of Proprietary Information as defined in the Confidentiality Agreement, to promptly return documents, and other property of Praxis and/or its affiliates, and to comply with your ongoing obligations regarding non-solicitation. A copy of the Confidentiality Agreement is attached as Exhibit A. You also acknowledge that your obligations regarding non-competition under your Noncompetition Agreement, attached hereto as Exhibit B, shall continue in full force and effect. Further, the Parties agree to incorporate into this Agreement the obligations further set out and attached hereto as Exhibit C with respect to non-solicitation obligations following the Separation Date (such obligations, together with the obligations set forth in Exhibit A and Exhibit B, the “Restrictive Covenants”). You further reaffirm and agree that you have at all times complied with and/or will continue to comply with the Restrictive Covenants.

 

4.Release of Claims

 

In consideration of the Severance Pay, to which you acknowledge you would otherwise not be entitled, you voluntarily release and forever discharge Praxis, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) generally from all suits, claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claim(s)”) that, as of the Separation Date, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees. This release includes, without limitation, any Claims arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever your employment by the Company or the separation thereof, including without limitation any and all claims arising under federal, state, or local laws relating to employment, claims of any kind that may be brought in any court or administrative agency, and any claims:

 

·relating to your employment by and ending of employment with Praxis;

 

·of wrongful discharge or violation of public policy;

 

·of breach of contract;

 

·of defamation or other torts;

 

·any claims arising under Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq.; the Equal Pay Act, as amended, 29 U.S.C. § 206(d);

 

·the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601 et seq.;

 

·The Age Discrimination in Employment Act of 1967, 29 U.S.C. §621 et seq. (“ADEA”);

 

 

 

 

·the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq.;

 

·the False Claims Act , 31 U.S.C. § 3729 et seq.;

 

·the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.;

 

·the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C. § 2101 et seq.;

 

·the Fair Labor Standards Act, 29 U.S.C. § 215 et seq.;

 

·the Sarbanes-Oxley Act of 2002;

 

·the Massachusetts Law Against Discrimination, G.L. c. 151B, as amended;

 

·the Massachusetts Equal Rights Act, G.L. c. 93, as amended;

 

·the Massachusetts Civil Rights Act, G.L. c. 12, as amended;

 

·the Massachusetts Privacy Statute, G.L. c. 214, § 1B, as amended;

 

·the Massachusetts Sexual Harassment Statute, G.L. c. 214, § 1C;

 

·the Massachusetts Wage Payment Statute, G.L. c. 149, §§ 148, 148A, 148B, 149, 150, 150A-150C, 151, 152, 152A, et seq.;

 

·the Massachusetts Wage and Hour laws, G.L. c. 151§1A et seq.;

 

·the Massachusetts Workers’ Compensation Act, G.L. c. 152, § 75B;

 

·the Massachusetts Small Necessities Act, G.L. c. 149, § 52D;

 

·the Massachusetts Equal Pay Act, G.L. c. 149, § 105A-C;

 

·the Massachusetts Equal Rights for the Elderly and Disabled, G.L. c. 93, § 103;

 

·the Massachusetts AIDS Testing statute, G.L. c. 111, §70F;

 

·the Massachusetts Consumer Protection Act, G.L. c. 93A;

 

·Massachusetts Employment Leave for Victims and Family Members of Abuse, G.L. c. 149, §52E, as amended;

 

·the Massachusetts Earned Sick Time Law, M.G.L. c. 149, § 148C;

 

·the Massachusetts Paid Family and Medical Leave Act, M.G.L. c.175M et seq.;

 

·the Massachusetts Parental Leave Act, G.L. c. 149, § 105D;

 

·the Massachusetts Age Discrimination Law, G.L. c. 149 §24 A et seq.;

 

·for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation or benefits, either under the Massachusetts Wage Act, M.G.L. c. 149, §§148- lS0C, or otherwise; and

 

·for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief or attorney’s fees;

 

provided, however, that this release shall not affect your vested rights under Praxis' Section 401(k) plan, your vested stock option or other stock-based awards under Praxis’ equity incentive plans (“Stock Option Documents”) or your rights under this Agreement.

 

You agree not to accept damages of any nature, other equitable or legal remedies for your own benefit or attorney's fees or costs from any of the Releasees with respect to any Claim released by this Agreement. As a material inducement to Praxis to enter into this Agreement, you represent that you have not assigned any Claim to any third party.

 

 

 

 

You acknowledge that you have been provided with all time off afforded to you under the law. You also acknowledge and agree that you have been paid all compensation you earned by virtue of your employment with Praxis. The Severance Pay is made in full satisfaction of any and all Claims for salary, wages, overtime, bonuses, commissions, vacation pay, paid time off, severance pay, bonus pay, incentive pay, or any other compensation or benefits to which you are or may claim to be entitled.

 

5.Confidentiality of Agreement-Related Information

 

You agree, to the fullest extent permitted by law, to keep all Agreement-Related Information completely confidential. “Agreement-Related Information” means any allegations of wrongful conduct by Praxis or any of its representatives, the negotiations leading to this Agreement and the existence and terms of this Agreement. Notwithstanding the foregoing, you may disclose Agreement-Related Information to your spouse, your attorney and your financial advisors, provided that they first agree for the benefit of Praxis, to keep Agreement-Related Information confidential. Nothing in this Section shall be construed to prevent you from disclosing Agreement-Related Information to the extent required by a lawfully issued subpoena or duly issued court order; provided that you provide Praxis with advance written notice and a reasonable opportunity to contest such subpoena or court order and that you share only the amount of Agreement-Related Information necessary to comply with such subpoena or duly issued court order.

 

6Non-Disparagement

 

You agree not to make any disparaging statements concerning Praxis or any of its affiliates or subsidiaries, products, services or current or former directors, officers, employees, advisors, agents, successors and permitted assigns or subsidiaries of Praxis.

 

7.Protected Disclosures and Other Protected Actions

 

Nothing contained in this Agreement limits your ability to file a charge or complaint with any federal, state or local governmental agency or commission (a “Government Agency”). In addition, nothing contained in this Agreement limits your ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including your ability to provide documents or other information, without notice to Praxis, nor does anything contained in this Agreement apply to truthful testimony in litigation. If you file any charge or complaint with any Government Agency and if the Government Agency pursues any Claim on your behalf, or if any other third party pursues any Claim on your behalf, you waive any right to monetary or other individualized relief (either individually or as part of any collective or class action). In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or the Confidentiality Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Neither the non-disclosure nor the non-disparagement obligations of this Agreement in any way limit your right, where applicable, to file or participate in an investigative proceeding conducted by the Equal Employment Opportunity Commission (EEOC) and/or Massachusetts Commission Against Discrimination (MCAD) and the National Labor Relations Board (NLRB) or other federal or state regulatory or law enforcement agency or in any way affect your obligation to testify truthfully in any legal proceeding.

 

8.Other Provisions

 

(a)           Termination of Payments. If you breach any of your obligations under this Agreement, in addition to any other legal or equitable remedies it may have for such breach, Praxis shall have the right to terminate any payments or health benefits to you or for your benefit under this Agreement. The termination of such payments or health benefits in the event of your breach will not affect your continuing obligations under this Agreement.

 

 

 

 

(b)           Absence of Reliance. In signing this Agreement, you are not relying upon any promises or representations made by anyone at or on behalf of Praxis that are not captured herein.

 

(c)           Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any Section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

(d)           Waiver. No waiver of any provision of this Agreement shall be effective unless made in writing and signed by the waiving party. The failure of a party to require the performance of any term or obligation of this Agreement, or the waiver by a party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

(e)           Relief. You agree that it would be difficult to measure any harm caused to Praxis that might result from any breach by you of your promises set forth in Sections 3, 4, 5, 6, 7, and 8 (the “Specified Sections”). You further agree that money damages would be an inadequate remedy for any breach of any of the Specified Sections. Accordingly, you agree that if you breach, or propose to breach, any portion of your obligations under any of the Specified Sections, Praxis shall be entitled, in addition to all other remedies it may have, to an injunction or other appropriate equitable relief to restrain any such breach, without showing or proving any actual damage to Praxis and without the necessity of posting a bond. If Praxis prevails in any action to enforce any of the Specified Sections, then you also shall be liable to Praxis for reasonable attorney’s fees and costs incurred by Praxis in enforcing any of the Specified Sections, except as to claims under the Age Discrimination in Employment Act.

 

(f)            Governing Law; Venue; Interpretation. This Agreement shall be interpreted and enforced under the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles. Any legal suit, action or proceeding arising out of or related to this Agreement shall be brought exclusively in the federal and state courts located in Boston, Massachusetts (and the appropriate appellate courts therefrom), and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding, and irrevocably waives any objection based on inconvenient forum or lack of personal jurisdiction. In the event of any dispute, this Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning, and not to be construed strictly for or against either you or Praxis or the “drafter” of all or any portion of this Agreement.

 

(g)           Entire Agreement. This Agreement constitutes the entire agreement between you and Praxis. This Agreement supersedes any previous agreements or understandings between you and Praxis, except the Stock Option Documents, the Confidentiality Agreement, the Nonsolicitation Agreement and any other obligations specifically preserved in this Agreement.

 

(h)           Acknowledgment of Waiver of Claims under ADEA. You understand and acknowledge that you are waiving and releasing any rights you may have under the ADEA, and that this waiver and release is knowing and voluntary. You understand and agree that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date you sign this Agreement. You understand and acknowledge that the consideration given for this waiver and release is in addition to anything of value to which you were already entitled. Praxis advises you to consult with an attorney before signing this Agreement. You understand and acknowledge that you have been given the opportunity to consider this Agreement for forty-five (45) days from your receipt of this Agreement before signing it (the “Consideration Period”). To accept this Agreement, you must return a signed original or a signed PDF copy of this Agreement so that it is received by Alex Nemiroff, General Counsel at or before the expiration of the Consideration Period. If you sign this Agreement before the end of the Consideration Period, you acknowledge that such decision was entirely voluntary and that you had the opportunity to consider this Agreement for the entire Consideration Period. For the period of seven (7) business days from the date when you sign this Agreement, you have the right to revoke this Agreement by written notice to Alex Nemiroff, General Counsel, provided that such notice is delivered so that it is received at or before the expiration of the seven (7) business day revocation period.

 

 

 

 

This Agreement shall not become effective or enforceable during the revocation period. This Agreement shall become effective on the first business day following the expiration of the revocation period (the “Effective Date”).

 

i)             Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. A signed copy of this Agreement, including by industry standard electronic signature software, delivered by facsimile, e-mail of a .pdf or other reliable means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement. Each party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed Agreement electronically or delivery by facsimile, e-mail of a .pdf or other reliable means of electronic transmission.

 

Please indicate your agreement to the terms of this Agreement by signing and returning to Praxis, the original or a PDF copy of this Agreement within the time period set forth above.

 

Sincerely,

 

/s/ Alex Nemiroff  

Alex Nemiroff

General Counsel

PRAXIS PRECISION MEDICINES, INC.

 

You are advised to consult with an attorney before signing this Agreement. This is a legal document. Your signature will commit you to its terms and obligations. By signing below, you acknowledge that you have carefully read and fully understand all of the provisions of this Agreement and that you are knowingly and voluntarily entering into this Agreement.

 

Read and Acknowledged

 

Signature: /s/ Nicole Sweeny  

 

Name: Nicole Sweeny

 

Date: 3/21/23

 

Enclosures

(Exhibit A): Confidentiality Agreement

(Exhibit B): Noncompetition Agreement

(Exhibit C): Additional Covenants regarding Non-solicitation

 

 

 

 

Exhibit A

 

Employee Confidentiality, Assignment and Nonsolicitation Agreement

 

[Intentionally omitted]

 

 

 

 

Exhibit B

 

Noncompetition Agreement

 

[Intentionally omitted]

 

 

 

 

Exhibit C

Additional Covenants

 

[Intentionally omitted] 

 

 

 

EX-101.SCH 3 prax-20230317.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 prax-20230317_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 prax-20230317_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm239181d2_ex10-1img001.jpg GRAPHIC begin 644 tm239181d2_ex10-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 17, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 17, 2023
Entity File Number 001-39620
Entity Registrant Name PRAXIS PRECISION MEDICINES, INC.
Entity Central Index Key 0001689548
Entity Tax Identification Number 47-5195942
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 99 High Street
Entity Address, Address Line Two 30th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 300-8460
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol PRAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm239181d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001689548 2023-03-17 2023-03-17 iso4217:USD shares iso4217:USD shares 0001689548 false 8-K 2023-03-17 PRAXIS PRECISION MEDICINES, INC. DE 001-39620 47-5195942 99 High Street 30th Floor Boston MA 02110 617 300-8460 false false false false Common Stock, $0.0001 par value per share PRAX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://praxismedicines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm239181d2_8k.htm prax-20230317.xsd prax-20230317_lab.xml prax-20230317_pre.xml tm239181d2_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm239181d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm239181d2_8k.htm" ] }, "labelLink": { "local": [ "prax-20230317_lab.xml" ] }, "presentationLink": { "local": [ "prax-20230317_pre.xml" ] }, "schema": { "local": [ "prax-20230317.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRAX", "nsuri": "http://praxismedicines.com/20230317", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239181d2_8k.htm", "contextRef": "From2023-03-17to2023-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://praxismedicines.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239181d2_8k.htm", "contextRef": "From2023-03-17to2023-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://praxismedicines.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-035170-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-035170-xbrl.zip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

].;R^M,/?JC37@8SL.O)D5EU8I,;Y$Z*3P^L3^U;] 3?#WO[? M#\2*,6%+SM[](JXNC^'EZ6#O9?]%/QS\C_K<[^WT]?2FU^MW_YC=/!'#\^N? MGY08NSZI3VTF>K8/*_G7]W('8*+]=!\0Y;Q">C(?C)(\3Z;FH15;7=U6L>Z_ MOQA&. D?4OE99^)#J@*=Z21NM]ZI4 \+NL./K^?S M>7=&=#"U>]\-DNGA[L?7%E9!IPW^N23^3TSJ>^&8#RLD2MR

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end